Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ

Barry M. Forman1, Jasmine Chen1, Ronald M. Evans1
1The Salk Institute for Biological Studies and Howard Hughes Medical Institute, Gene Expression Laboratory, 10010 North Torrey Pines Road, La Jolla, CA 92037

Tóm tắt

Fatty acids (FAs) and their derivatives are essential cellular metabolites whose concentrations must be closely regulated. This implies that regulatory circuits exist which can sense changes in FA levels. Indeed, the peroxisome proliferator-activated receptor α (PPARα) regulates lipid homeostasis and is transcriptionally activated by a variety of lipid-like compounds. It remains unclear as to how these structurally diverse compounds can activate a single receptor. We have developed a novel conformation-based assay that screens activators for their ability to bind to PPARα/δ and induce DNA binding. We show here that specific FAs, eicosanoids, and hypolipidemic drugs are ligands for PPARα or PPARδ. Because altered FA levels are associated with obesity, atherosclerosis, hypertension, and diabetes, PPARs may serve as molecular sensors that are central to the development and treatment of these metabolic disorders.

Từ khóa


Tài liệu tham khảo

Durrington P. N. (1993) Postgrad. Med. J. 69 (Suppl 1) S18–S25; discussion S25–S29.

G M Reaven J Intern Med Suppl 736, 13–22 (1994).

10.1016/0005-2760(96)00066-5

10.1038/347645a0

10.1128/MCB.15.6.3012

10.1016/0092-8674(95)90200-7

10.1038/358771a0

10.1016/0092-8674(95)90193-0

10.1016/0092-8674(95)90194-9

10.1074/jbc.271.16.9455

10.1073/pnas.89.10.4653

M H Hsu, C N Palmer, K J Griffin, E F Johnson Mol Pharmacol 48, 559–567 (1995).

10.1016/0006-2952(93)90607-X

10.1016/0092-8674(95)90530-8

10.1073/pnas.91.15.7355

10.1146/annurev.pa.13.040173.001443

10.1038/366476a0

10.1128/mcb.14.5.3329-3338.1994

10.1038/358587a0

L C Groop, R C Bonadonna, D C Simonson, A S Petrides, M Shank, R A DeFronzo Am J Physiol 263, E79–E84 (1992).

10.1111/j.1432-1033.1979.tb13173.x

10.1042/bj2840289

10.1016/0006-2952(91)90010-3

10.1016/0005-2760(94)90095-7

10.1111/j.1432-1033.1994.tb18773.x

10.1016/0005-2760(87)90088-9

10.1073/pnas.91.23.11012

10.1016/0005-2760(93)90285-H

10.1042/bj2520409

10.1042/bj2410751

10.1016/S0021-9258(17)42763-3

10.1042/bj2700167

10.1074/jbc.270.41.23975

10.1111/j.1432-1033.1996.00242.x

10.1101/gad.10.8.974

10.1016/S0021-9258(17)36979-X

10.1038/384039a0

10.1016/0022-2836(72)90253-7

10.1016/S0021-9258(19)40111-7

10.1016/S0021-9258(18)98471-1

10.1016/0005-2760(91)90292-P

10.1007/BF02535987

10.1146/annurev.nu.13.070193.002035

10.1016/0027-5107(95)00136-0

10.1016/S0022-2275(20)40103-8

M Liimatta, H C Towle, S Clarke, D B Jump Mol Endocrinol 8, 1147–1153 (1994).

10.1074/jbc.271.1.218